膀胱肉瘤样癌组织RASAL2、GATA6、ASCL2表达与临床病例特征及预后的关系  

Expressions of RASAL2,GATA6 and ASCL2 in Bladder Sarcomatoid Carcinoma and Their Relationshipswith Clinical Features and Prognosis

作　　者：张莉[1] 周丽 季星利 崔家旗 杨帆[1] ZHANG Li;ZHOU Li;JI Xingli;CUI Jiaqi;YANG Fan(Department of Pathology,Chengdu Fifth People’s Hospital,Chengdu 611130,China)

机构地区：[1]成都市第五人民医院病理科,四川成都611130

出　　处：《标记免疫分析与临床》2022年第3期438-442,共5页Labeled Immunoassays and Clinical Medicine

基　　金：四川省科技厅科技支撑项目(编号:2013SZ0044)。

摘　　要：目的探讨膀胱肉瘤样癌组织患者大鼠肉瘤蛋白活化因子2(RASAL2)、转录调节因子(GATA6)、转录因子(ASCL2)表达与临床病理特征及预后的关系。方法收集2016年9月至2017年9月期间本院收治的82例膀胱肉瘤样癌患者为研究对象,采用免疫组化法检测患者膀胱肉瘤样癌组织和癌旁组织中RASAL2、GATA6、ASCL2的表达情况,统计对比膀胱肉瘤样癌组织和癌旁组织中各蛋白的阳性表达率,并分析RASAL2、GATA6、ASCL2与膀胱肉瘤样癌临床病理特征间的关系,并对患者进行随访观察,分析RASAL2、GATA6、ASCL2表达与预后的关系。结果膀胱肉瘤样癌组织中的RASAL2阳性表达率低于癌旁组织,GATA6、ASCL2阳性表达率高于癌旁组织(P<0.05)。膀胱肉瘤样癌患者RASAL2、GATA6、ASCL2阳性表达水平与患者的年龄、肿瘤大小等差异无统计学意义(P>0.05),在不同分化程度、不同分期、有无淋巴结转移患者中RASAL2、GATA6、ASCL2阳性表达率比较差异有统计学意义(P<0.05)。随访观察显示,膀胱肉瘤样癌RASAL2阴性表达患者3年生存率低于阳性表达患者,GATA6、ASCL2阳性表达患者3年生存率低于阴性表达患者(P<0.05)。结论在膀胱肉瘤样癌患者中RASAL2呈现低表达,GATA6、ASCL2呈现高表达,与膀胱肉瘤样癌的发生发展、转移、分期及预后有密切关联,RASAL2、GATA6、ASCL2有望成为膀胱肉瘤样癌患者预后效果判断的参考指标。Objective To explore the relationship between the expressions of sarcoma protein activator 2(RASAL2),transcription regulator(GATA6),transcription factor(ASCL2)and clinicopathological characteristics and prognosis in patients with bladder sarcomatoid carcinoma.Methods We collected 82 patients with sarcomatoid carcinoma of the bladder who were admitted to our hospital from 09/2016 to 09/2017 as the research objects.Immunohistochemistry was conducted to detect the expressions of RASAL2,GATA6,and ASCL2 in patients’bladder sarcomatoid carcinoma and adjacent tissues,and results were statistically compared for the positive expression rate of each protein in sarcomatoid carcinoma tissue and adjacent tissues,and we analyzed the relationship between RASAL2,GATA6,ASCL2 and clinicopathological characteristics of bladder sarcomatoid carcinoma,and conducted a follow-up observation among patients to analyze the expression of RASAL2,GATA6,ASCL2 and their relationship with prognosis.Results The positive expression rate of RASAL2 in bladder sarcomatoid carcinoma tissue was lower than that in adjacent tissues,and the positive expression rates of GATA6 and ASCL2 were higher than those in adjacent tissues(P<0.05).The positive expression levels of RASAL2,GATA6 and ASCL2 in patients with bladder sarcomatoid carcinoma were not significantly different across groups of age and tumor size(P>0.05).RASAL2,GATA6 and ASCL2 were found in patients with different levels of differentiation,different stages,and lymph node metastasis,in which their positive expression rates were statistically different(P<0.05).The follow-up observations showed that the 3-year survival rate of patients with negative expression of RASAL2 of bladder sarcomatoid carcinoma was lower than that of positive expression patients,and the 3-year survival rate of patients with positive expression of GATA6 and ASCL2 was lower than that of negative expression patients(P<0.05).Conclusion In patients with bladder sarcomatoid carcinoma,RASAL2 has a low expression,while GATA6 and AS

关 键 词：膀胱肉瘤样癌 大鼠肉瘤蛋白活化因子2 转录调节因子 转录因子 临床病理特征 预后 

分 类 号：R737.14[医药卫生—肿瘤]